Business Description
F-star Therapeutics Inc
NAICS : 325412
SIC : 2834
Description
Financial Strength
5/10
Name | Current | Vs Industry | Vs History | |||
---|---|---|---|---|---|---|
Cash-To-Debt | 2.81 | |||||
Equity-to-Asset | 0.68 | |||||
Debt-to-Equity | 0.22 | |||||
Debt-to-EBITDA | -0.29 | |||||
Piotroski F-Score | N/A/9 | |||||
Altman Z-Score | 0.39 | |||||
Beneish M-Score | 1.38 | |||||
WACC vs ROIC |
Growth Rank
Name | Current | Vs Industry | Vs History |
---|
Momentum Rank
Name | Current | Vs Industry | Vs History | |||
---|---|---|---|---|---|---|
6-1 Month Momentum % | -16.58 | |||||
12-1 Month Momentum % | 45.19 |
Liquidity Ratio
Name | Current | Vs Industry | Vs History | |||
---|---|---|---|---|---|---|
Current Ratio | 3.38 | |||||
Quick Ratio | 3.38 | |||||
Cash Ratio | 2.42 |
Dividend & Buy Back
Name | Current | Vs Industry | Vs History | |||
---|---|---|---|---|---|---|
Shareholder Yield % | -4 |
Profitability Rank
Name | Current | Vs Industry | Vs History | |||
---|---|---|---|---|---|---|
Operating Margin % | -173.56 | |||||
Net Margin % | -211.32 | |||||
FCF Margin % | -179.05 | |||||
ROE % | -55.42 | |||||
ROA % | -41.67 | |||||
ROIC % | -86.67 | |||||
ROC (Joel Greenblatt) % | -1132.59 | |||||
ROCE % | -46.45 |
GF Value Rank
Name | Current | Vs Industry | Vs History | |||
---|---|---|---|---|---|---|
PS Ratio | 6.99 | |||||
PB Ratio | 2.75 | |||||
Price-to-Tangible-Book | 5.88 | |||||
EV-to-EBIT | -3.04 | |||||
EV-to-EBITDA | -3.09 | |||||
EV-to-Forward-EBITDA | -0.99 | |||||
EV-to-Revenue | 6.31 | |||||
EV-to-Forward-Revenue | 26.72 | |||||
EV-to-FCF | -3.52 | |||||
Price-to-Net-Current-Asset-Value | 6.85 | |||||
Price-to-Net-Cash | 17.8 | |||||
Earnings Yield (Greenblatt) % | -32.89 | |||||
FCF Yield % | -25.26 |
Historical Operating Revenue by Business Segment
Historical Operating Revenue by Geographic Region
Guru Trades
See DetailsInsider Trades
See DetailsGurus Latest Trades with NAS:FSTX
You need a Premium membership or above to view this section.
Take a 7-Day Free Trial
No Available Data
Peter Lynch Chart
Performance
Annualized Return % Â
Total Annual Return % Â
F-star Therapeutics Inc Executives
DetailsGF Value
Analyst Estimate
Key Statistics
Name | Value | ||
---|---|---|---|
Revenue (TTM) (Mil $) | 21.175 | ||
EPS (TTM) ($) | -1.82 | ||
Beta | 0 | ||
Volatility % | 122.83 | ||
14-Day RSI | 0 | ||
14-Day ATR ($) | 0.217857 | ||
20-Day SMA ($) | 0 | ||
12-1 Month Momentum % | 45.19 | ||
52-Week Range ($) | 2.07 - 7.12 | ||
Shares Outstanding (Mil) | 21.98 |
Piotroski F-Score Details
Component | Result | ||
---|---|---|---|
Piotroski F-Score | 9999 | ||
Positive ROA | |||
Positive CFROA | |||
Higher ROA yoy | |||
CFROA > ROA | |||
Lower Leverage yoy | |||
Higher Current Ratio yoy | |||
Less Shares Outstanding yoy | |||
Higher Gross Margin yoy | |||
Higher Asset Turnover yoy |
F-star Therapeutics Inc Filings
Filing Date | Document Date | Form | ||
---|---|---|---|---|
No Filing Data |
F-star Therapeutics Inc Stock Events
Event | Date | Price($) | ||
---|---|---|---|---|
No Event Data |
F-star Therapeutics Inc Frequently Asked Questions
What is F-star Therapeutics Inc(FSTX)'s stock price today?
When is next earnings date of F-star Therapeutics Inc(FSTX)?
Does F-star Therapeutics Inc(FSTX) pay dividends? If so, how much?
Press Release
Subject | Date | |||
---|---|---|---|---|
No Press Release |